Atlantanews Online

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Ulcerative Colitis Market Report

• In the United States, the total number of Ulcerative Colitis diagnosed prevalent cases was 1,437,600 in 2022.
• In the 7MM, approximately 86% of the patient share is attributed to the 18–64 age group.
• The increase in Ulcerative Colitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Ulcerative Colitis Market is anticipated to witness growth at a considerable CAGR.
• The leading Ulcerative Colitis Companies working in the market include Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and others.
• Promising Ulcerative Colitis Therapies in the various stages of development include Etrasimod, Adalimumab, Budesonide MMX® 6 mg, Tralokinumab, and others.
• April 2024:- Pfizer announced a study of Phase 3 clinical trials for Etrasimod. An Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis. The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
• January 2024:- Adacyte Therapeutics SL- Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis. The primary endpoint will be evaluated through the following variables: PUCAI score, IFX levels, and steroid treatment.

Discover which therapies are expected to grab the Ulcerative Colitis Market Share @ Ulcerative Colitis Market Outlook

Ulcerative Colitis Overview

Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that primarily affects the colon and rectum. It causes inflammation and ulcers in the innermost lining of the large intestine, leading to symptoms such as abdominal pain, diarrhea (often with blood or pus), rectal bleeding, urgency to defecate, weight loss, fatigue, and sometimes fever. The exact cause of ulcerative colitis is unknown, but it’s believed to involve a combination of genetic, environmental, and immune factors. Treatment typically involves medications to reduce inflammation and manage symptoms, although in severe cases, surgery to remove the affected portion of the colon may be necessary.

Ulcerative Colitis Epidemiology Insights

The epidemiology section of Ulcerative Colitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• Total Ulcerative Colitis Diagnosed Prevalent Cases
• Ulcerative Colitis Age-specific Cases
• Ulcerative Colitis Severity-specific Cases
• Total Ulcerative Colitis Treated Patients

Download the report to understand which factors are driving Ulcerative Colitis Epidemiology trends @ Ulcerative Colitis Epidemiological Insights

Ulcerative Colitis Marketed Drugs

• SIMPONI (golimumab): Janssen Pharmaceuticals
• ENTYVIO (vedolizumab): Takeda Pharmaceuticals

Ulcerative Colitis Emerging Drugs

• Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
• ABX464 (obefazimod): Abivax

Ulcerative Colitis Drugs Market

The Ulcerative Colitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Ulcerative Colitis signaling in Ulcerative Colitis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Ulcerative Colitis Treatment Market Landscape

The Ulcerative Colitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Ulcerative Colitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Ulcerative Colitis treatment guidelines, visit @ Ulcerative Colitis Treatment Market Landscape

Ulcerative Colitis Market Outlook

The report’s outlook on the Ulcerative Colitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Ulcerative Colitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Ulcerative Colitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Ulcerative Colitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Ulcerative Colitis Drugs Uptake

The drug chapter of the Ulcerative Colitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Ulcerative Colitis.

Major Ulcerative Colitis Companies

Several Ulcerative Colitis Companies working in the market include Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and others.

Learn more about the FDA-approved drugs for Ulcerative Colitis @ Drugs for Ulcerative Colitis Treatment

Scope of the Ulcerative Colitis Market Report

• Coverage- 7MM
• Ulcerative Colitis Companies- Janssen Pharmaceuticals, Takeda Pharmaceuticals, Pfizer, EA Pharma, Kissei Pharma, Gilead Sciences, Galapagos NV, Celgene (Bristol-Myers Squibb), AbbVie, Arena Pharmaceuticals, Reistone Biopharma, Landos Biopharma, Bridge Biotherapeutics, Applied Molecular Transport, AbGenomics (AltruBio), Abivax, Connect Biopharma, Boehringer Ingelheim, Eli Lilly and Company, InDex Pharmaceuticals, Bristol-Myers Squibb, Protagonist Therapeutics, Mesoblast Ltd, and others.
• Ulcerative Colitis Therapies- Etrasimod, Adalimumab, Budesonide MMX® 6 mg, Tralokinumab, and others.
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis Market Drivers and Barriers
• Ulcerative Colitis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Ulcerative Colitis Drugs in development @ Ulcerative Colitis Clinical Trials Assessment

Table of Content

1. Key Insights

2. Report Introduction

3. Ulcerative Colitis Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Ulcerative Colitis Executive Summary

6. Ulcerative Colitis Market Disease Background and Overview

7. Ulcerative Colitis Epidemiology and Patient Population

8. Patient Journey

9. Ulcerative Colitis Marketed Therapies

10. Ulcerative Colitis Emerging Drugs

11. Ulcerative Colitis: The 7MM Analysis

12. Ulcerative Colitis Market Access and Reimbursement

13. Ulcerative Colitis KOL Views

14. Ulcerative Colitis SWOT Analysis

15. Ulcerative Colitis Unmet Needs

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/